-+ 0.00%
-+ 0.00%
-+ 0.00%

Elicio Therapeutics to Present Phase 2 Pancreatic Cancer Vaccine Results at SITC 2026

PUBT·10/29/2026 13:04:16
Elicio Therapeutics to Present Phase 2 Pancreatic Cancer Vaccine Results at SITC 2026
  • Elicio Therapeutics will present Phase 2 AMPLIFY-7P results for camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer at SITC in Phoenix, November 4-8, 2026.
  • The randomized trial linked vaccine-induced immune responses to improved clinical outcomes; clinical presentations are scheduled for November 6 and 7.
  • A November 7 preclinical presentation will report durable antitumor activity from direct tumor delivery of amphiphilic immunomodulators.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290900PRIMZONEFULLFEED9851836) on October 29, 2026, and is solely responsible for the information contained therein.